Impact of the sulfonylurea receptor 1 (SUR1) exon 16-3c/t polymorphism on acute hyperglycaemia in type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 77, Issue 2, 2007, Pages 258-262

  Dworacka, Marzena ^a   Winiarska, Hanna ^a   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

1,5 Anhydro d glucitol; Acute hyperglycaemia; Diabetes type 2; SUR1 gene polymorphism

Indexed keywords

1,5 ANHYDROSORBITOL; ACARBOSE; C PEPTIDE; GLICLAZIDE; INSULIN; METFORMIN; PROINSULIN; SULFONYLUREA RECEPTOR 1;

ADULT; AGED; ALCOHOL BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; EXON; GENETIC VARIABILITY; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE OF ONSET; ATP-BINDING CASSETTE TRANSPORTERS; BODY MASS INDEX; CYTOSINE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; HUMANS; HYPOGLYCEMIA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; RISK FACTORS; THYMINE;

EID: 34247588583     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.12.002     Document Type: Article

References (38)

1. Balkau B., Bertrain S., Ducimetiere P., and Eschwege E. Is there a glycemic threshold for mortality risk?. Diabetes Care 22 (1999) 696-699
2. Balkau B., Shipley M., Jarret R.J., Pyörälä K., Pyörälä M., Forhan M., et al. High glucose concentration is a risk factor for mortality in middle-age nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21 (1998) 331-333
3. Barzilay J.L., Spiekerman C.F., Wahl P.W., Kuller L.H., Cushman M., Furberg C.D., et al. Cardiovascular disease in older adults with glucose disorders: comparison of the American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354 (1999) 622-625
4. Barret-Connor E., and Ferrara A. Isolated postchallenged hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 21 (1998) 1236-1239
5. Tenerz A., Norhammar A., Silveira A., Hamsten A., Nilsson G., Ryden L., et al. Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 26 (2003) 2770-2776
6. The, DECODE Study Group on behalf of the European Diabetes Epidemiology Group, glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria. Arch. Intern. Med. 161 (2001) 397-405
7. 1c level. Diabetes Care 23 (2000) 1830-1834
8. Yamanouchi T., Inoue T., Ogata E., Kashiwabara A., Ogata N., Kashiwabara A., et al. Post-load glucose measurements in oral glucose tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin. Sci. 101 (2001) 227-233
9. Dworacka M., Winiarska H., Szymańska M., Kuczyński S., Szczawińska K., Wierusz-Wysocka B., et al. 1,5-Anhydro-d-glucitol: a novel marker of glucose excursions. Intern. J. Clin. Pract. suppl 129 (2002) 40-44
10. Dworacka M., and Winiarska H. The application of plasma 1,5-anhydro-d-glucitol (1,5-AG) for monitoring type 2 diabetic patients. Dis. Markers 21 (2005) 127-132
11. Buse J.B., and Freeman J.L.R. Serum 1,5-anhydroglucitol (GlycoMark™): a short-term glycemic marker. Diabetes Technol. Ther. 5 (2003) 355-363
12. Yamanouchi T., and Akanuma Y. Serum 1,5-anhydro-d-glucitol: new clinical marker for glycemic control. Diabet. Res. Clin. Pract. 24 suppl (1994) 261-268
13. Yamanouchi T., Tachibana Y., Akanuma H., Minoda S., Shinohara T., Moromizato H., et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am. J. Physiol. 263 (1992) E268-E273
14. 1c interrelationships in type 2 diabetes. Diabetes Care 24 (2001) 2023-2029
15. Suzuki H., Fukushima M., Usami M., Ikeda M., Taniguchi A., Nakai Y., et al. Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 26 (2003) 1211-1215
16. Woerle H.J., Szoke E., Meyer C., Dostou J.M., Wittlin S.D., Gosmanov N.R., et al. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 290 (2005) E67-E77
17. KATP: an inward rectifier sububit plus the sulfonylurea receptor. Science 270 (1995) 1166-1170
18. Davies S.N. Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas. In: Goodman, and Gilman's (Eds). The Pharmacological Basis of Therapeutics. 10th ed. (2005), The McGraw-Hill Companies 1613-1646
19. t'Hart L.M., Dekker J.M., van Haeften T.W., Ruige J.B., Stehouwer C.D.A., Erkelens D.W., et al. Reduced second phase insulin secretion in cariers of a sulphonylurea receptor gene variant associating with type II diabetes mellitus. Diabetologia 43 (2000) 515-519
20. Reis A.F., Hani E.H., Beressi N., Robert J.J., Bresson J.L., Froguel P., et al. Allelic variation in exon 18 of the sulfonylurea receptor 1 (SUR1) gene, insulin secretion and insulin sensitivity in nondiabetic relatives of type 2 diabetic patients. Diabetes Metab. 28 (2002) 209-215
21. Reis A.F., and Velho G. Sulfonylurea receptor-1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus. Diabetes Metab. 28 (2002) 14-19
22. Weisnagel S.J., Rankinen T., Nadeau A., Rao D.C., Chagnon Y.C., Perusse L., et al. Decreased fasting and oral glucose stimulated C-peptide in nondiabetic subjects with sequence variants in the sulfonylurea receptor gene. Diabetes 50 (2001) 697-702
23. Zychma M.J., Gumprecht J., Strojek K., Grzeszczak W., Moczulski D., Trautsolt W., et al. Sulfonylurea receptor gene 16-3 polymorphism-association with sulfonylurea and insulin treatment in type 2 diabetic patients. Med. Sci. Monit. 8 (2002) CR512-CR515
24. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetes Med. 16 (1999) 716-730
25. Yabuuchi M., and Masuda M. Simple enzymatic method for determining 1,5-anhydro-d-glucitol for diagnosis of diabetes mellitus. Clin. Chem. 35 (1984) 2039-2943
26. Dworacka M., Szczawińska K., Winiarska H., and Kuczyński S. The application of enzymatic method for 1,5-anhydro-d-glucitol estimation in plasma. Diagnostyka Laboratoryjna 33 (1997) 269-276
27. Pfützner A. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27 (2004) 682-687
28. Rachman J., Levy J.C., Barrow B.A., Manley S.E., and Turner R.C. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Diabetes 46 (1997) 1557-1562
29. Roder M.E., Porte D.J., Schwartz R.S., and Kahn S.E. Disproportionally elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with non-insulin dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 83 (1998) 604-608
30. Matthews D.R., Hosker J.P., Rudensky A.S., Naylor B.A., Treacher D.F., Turner R.C., et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
31. Miller S.A., Dykes D.D., and Polesky H.F. A simple saling out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16 (1988) 1215
32. Hansen T., Echwald S.M., Hansen L., Meller A.M., Almind K., Clausen K.J.O., et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 47 (1998) 598-605
33. Stern M.P., Ravindranath D., Braxton D.M., Reinhard L.J., Shivakumar S., Shipman P.A., et al. Evidence for linkage of region on chromosome 6 and 11 to plasma glucose concentrations in Mexican Americans. Genome Res. 6 (1996) 724-734
34. van Dam R.M., Hoebee B., Seidel J.C., Schlap M.M., de Bruin T.W., and Feskens E.J. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabetes Med. 22 (2005) 590-598
35. Yokoi N., Kanamori M., Horikawa Y., Takeda J., Snake T., Furuta H., et al. Association studies of variants in the genes involved in pancreatic beta-cell function in type 2 diabetes in Japanese subjects. Diabetes 55 (2006) 2379-2386
36. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 46 suppl 1 (2003) M2-M8
37. 't Hart L.M., Ruige J.B., Dekker J.M., Nijpels G., Maasen J.A., and Heine R.J. Reduced beta-cell function and blond pressure in carriers intron 16-3t variant of the sulfonylurea receptor gene. Diabetologia 41 suppl 1 (1998) A33 (abstract)
38. Inoue H., Ferrer J., Welling C.M., Elbein S.C., Hoffman M., Mayorga R., et al. Sequence variants in sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 45 (1996) 825-831